8-KEarnings & ResultsExhibits & Filings

AMGEN INC 8-K Report, Financial Results (May 1, 2025)

Filed May 1, 2025For Securities:AMGN

Summary

Amgen Inc. (AMGN) has filed an 8-K report detailing its first-quarter 2025 financial results, announced on May 1, 2025. The report primarily furnishes the company's earnings press release, which includes a discussion of both GAAP and non-GAAP financial measures. Investors should note that Amgen provides non-GAAP earnings per share, operating income, operating margin, tax rate, and operating expenses to offer a more comprehensive view of its ongoing business performance and facilitate comparisons across periods. Free Cash Flow (FCF) is also presented as a measure of liquidity. The company outlines the specific costs excluded from GAAP to arrive at these non-GAAP figures, including acquisition-related expenses (such as amortization and impairment of acquired intangible assets and inventory), restructuring and cost savings initiatives (severance, asset impairments), and other items outside the ordinary course of business (investment gains/losses, legal settlements). Amgen believes these adjustments provide a more meaningful evaluation of current and past operating performance by excluding items that can be inconsistent or non-recurring.

Key Highlights

  • 1Amgen released its first-quarter 2025 financial results on May 1, 2025, via an 8-K filing.
  • 2The report includes both GAAP and non-GAAP financial measures, with a focus on providing supplemental insights into operational performance.
  • 3Key non-GAAP metrics disclosed include non-GAAP earnings per share, operating income, and operating margin.
  • 4The company also presented Free Cash Flow (FCF) as an indicator of liquidity.
  • 5Amgen details specific exclusions from GAAP to calculate non-GAAP figures, such as acquisition-related costs and restructuring charges.
  • 6The press release aims to enhance investor understanding by facilitating comparisons of ongoing business operations.
  • 7This filing primarily consists of the earnings press release and is furnished as Exhibit 99.1.

Frequently Asked Questions

The primary purpose of this 8-K filing is to furnish Amgen's first-quarter 2025 earnings press release, which details the company's financial results and condition as of March 31, 2025. It provides both GAAP and non-GAAP financial information to investors.

Amgen provides non-GAAP earnings per share, operating income, operating margin, tax rate, and operating expenses. The company uses these measures to offer a more insightful view of its ongoing business operations, enabling better comparisons across different periods by excluding items like acquisition-related costs, restructuring charges, and other non-recurring items.

Amgen excludes acquisition-related expenses (such as amortization and impairment of acquired intangibles and inventory), costs associated with restructuring and cost-saving initiatives (like severance and facility charges), and other non-ordinary course items (e.g., gains/losses on investments, legal settlements). These adjustments are made to provide a clearer picture of the company's core operational performance.

No, this 8-K filing primarily contains the earnings press release and does not include new detailed financial statements or audit reports. The financial information provided is a summary of the company's unaudited results for the first quarter of 2025.